VYLOY (zolbetuximab) with Chemotherapy, Now Available for First-Line Treatment of Eligible Adult patients with Gastric and GEJ Adenocarcinoma in India
Jul 30, 2026
Mumbai (Maharashtra) [India], July 30: Astellas Pharma India today announced that VYLOY (zolbetuximab) in combination with chemotherapy is now available for the first-line treatment of adult patients with gastric or gastroesophageal junction adenocarcinoma whose tumors are HER2 negative and CLDN18.2 positive in India. This is the first and only approved therapy in India to offer extended survival benefit in combination with chemotherapy, the current standard of care for first-line treatment of adult gastric or gastroesophageal junction adenocarcinoma whose tumors are HER2 negative and CLDN18.2 positive.
Read More...
